Literature DB >> 25778500

Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines.

David J Tunnicliffe1, Davinder Singh-Grewal2, Siah Kim1, Jonathan C Craig1, Allison Tong1.   

Abstract

OBJECTIVE: Management of systemic lupus erythematosus (SLE) is complex and variability in practices exists. Guidelines have been developed to help improve the management of SLE patients, but there has been no formal evaluation of these guidelines. This study aims to compare the scope, quality, and consistency of clinical practice guidelines on the diagnosis, monitoring, and treatment of patients with SLE.
METHODS: Electronic databases were searched up to April 2014. The Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument and textual synthesis was used to appraise and compare recommendations.
RESULTS: Nine clinical practice guidelines and 5 consensus statements were identified, which covered 7 topics: diagnosis, monitoring, treatment, neuropsychiatric SLE, lupus nephritis, antiphospholipid syndrome, and other manifestations of lupus. The methodological quality of the guidelines was variable, with the overall mean AGREE II scores ranging from 31% to 75%, out of a maximum 100%. Scores were consistently low for applicability, with only 1 guideline scoring above 50%. There was substantial variability in the treatments recommended for class II and V lupus nephritis, the recommended duration of maintenance therapy for class III/IV lupus nephritis (from 1 to 4 years), and timing of ophthalmologic examination for patients taking corticosteroids.
CONCLUSION: Published guidelines on SLE cover a complex area of clinical care, but the methodological quality, scope, and recommendations varied substantially. Collaborative and multidisciplinary efforts to develop comprehensive, high-quality evidence-based guidelines are needed to promote best treatment and health outcomes for patients with SLE.
© 2015, American College of Rheumatology.

Entities:  

Mesh:

Year:  2015        PMID: 25778500     DOI: 10.1002/acr.22591

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  35 in total

1.  Impact of follow-up visits on disease outcome in Chinese systemic lupus erythematosus.

Authors:  Huanhuan Ma; Jing Dong; Liqin Wang; Lei Zhao; Lin Pan
Journal:  Clin Rheumatol       Date:  2017-08-03       Impact factor: 2.980

2.  HMGB1-C1q complexes regulate macrophage function by switching between leukotriene and specialized proresolving mediator biosynthesis.

Authors:  Tianye Liu; Alec Xiang; Travis Peng; Amanda C Doran; Kevin J Tracey; Betsy J Barnes; Ira Tabas; Myoungsun Son; Betty Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-30       Impact factor: 11.205

3.  Diagnostic accuracy of miRNAs as potential biomarkers for systemic lupus erythematosus: a meta-analysis.

Authors:  Zi-Wei Dai; Hong Wang; Wen-Juan Xu; Zhi-Hui Wang; Sheng-Qian Xu; Bin Wang; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2018-07-06       Impact factor: 2.980

4.  Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.

Authors:  Seyed Mostafa Monzavi; Aida Alirezaei; Zhaleh Shariati-Sarabi; Jalil Tavakol Afshari; Mahmoud Mahmoudi; Banafsheh Dormanesh; Faezeh Jahandoost; Ali Reza Khoshdel; Ali Etemad Rezaie
Journal:  Inflammopharmacology       Date:  2018-07-10       Impact factor: 4.473

5.  Clinical associations of proinflammatory cytokines, oxidative biomarkers and vitamin D levels in systemic lupus erythematosus.

Authors:  R Willis; M Smikle; K DeCeulaer; Z Romay-Penabad; E Papalardo; P Jajoria; B Harper; V Murthy; M Petri; E B Gonzalez
Journal:  Lupus       Date:  2017-05-03       Impact factor: 2.911

6.  Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.

Authors:  Candace H Feldman; Jamie Collins; Zhi Zhang; Chang Xu; S V Subramanian; Ichiro Kawachi; Daniel H Solomon; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-11       Impact factor: 4.794

7.  Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus.

Authors:  Ying Liu; Feng Zhan; Xiao Zhang; Shudian Lin
Journal:  Exp Ther Med       Date:  2017-10-31       Impact factor: 2.447

8.  Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus.

Authors:  E M Cohen; K D'Silva; D Kreps; M B Son; K H Costenbader
Journal:  Lupus       Date:  2018-02-16       Impact factor: 2.911

9.  Association of severe and therapy-refractory systemic lupus erythematosus and neuromyelitis optica: a management challenge.

Authors:  Inês Furtado; Guiomar Pinheiro; Ana Campar; Teresa Mendonça
Journal:  BMJ Case Rep       Date:  2018-06-04

10.  Perfusion image guided mechanical thrombectomy combined with tirofiban successfully revascularize systemic lupus erythematosus related acute large vessel occlusion: A case report.

Authors:  Han Wang; Haitao Hu; Jing Xu; Cong Qian
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.